Clinuvel Pharmaceuticals Limited CUV.AX Stock
Clinuvel Pharmaceuticals Limited Price Chart
Clinuvel Pharmaceuticals Limited CUV.AX Financial and Trading Overview
| Clinuvel Pharmaceuticals Limited stock price | 15.04 AUD |
| Previous Close | 18.86 AUD |
| Open | 19 AUD |
| Bid | 18.45 AUD x 0 |
| Ask | 18.52 AUD x 0 |
| Day's Range | 18.49 - 19 AUD |
| 52 Week Range | 13.46 - 28.72 AUD |
| Volume | 85.04K AUD |
| Avg. Volume | 73.48K AUD |
| Market Cap | 914.09M AUD |
| Beta (5Y Monthly) | 0.877011 |
| PE Ratio (TTM) | 46.25 |
| EPS (TTM) | 0.57 AUD |
| Forward Dividend & Yield | 0.04 (0.22%) |
| Ex-Dividend Date | September 6, 2022 |
| 1y Target Est | 30.19 AUD |
CUV.AX Valuation Measures
| Enterprise Value | 756.24M AUD |
| Trailing P/E | 46.25 |
| Forward P/E | 28.46154 |
| PEG Ratio (5 yr expected) | N/A |
| Price/Sales (ttm) | 12.894467 |
| Price/Book (mrq) | 6.5672703 |
| Enterprise Value/Revenue | 10.668 |
| Enterprise Value/EBITDA | 18.473 |
Trading Information
Clinuvel Pharmaceuticals Limited Stock Price History
| Beta (5Y Monthly) | 0.877011 |
| 52-Week Change | 30.60% |
| S&P500 52-Week Change | 20.43% |
| 52 Week High | 28.72 AUD |
| 52 Week Low | 13.46 AUD |
| 50-Day Moving Average | 19.41 AUD |
| 200-Day Moving Average | 20.58 AUD |
CUV.AX Share Statistics
| Avg. Volume (3 month) | 73.48K AUD |
| Avg. Daily Volume (10-Days) | 62.02K AUD |
| Shares Outstanding | 49.41M |
| Float | 37.13M |
| Short Ratio | N/A |
| % Held by Insiders | 20.55% |
| % Held by Institutions | 8.87% |
| Shares Short | N/A |
| Short % of Float | N/A |
| Short % of Shares Outstanding | N/A |
Dividends & Splits
| Trailing Annual Dividend Rate | 0.04 |
| Trailing Annual Dividend Yield | 0.21% |
| 5 Year Average Dividend Yield | N/A |
| Payout Ratio | 0.062 |
| Last Split Factor | 1:10 |
Financial Highlights
Fiscal Year
| Fiscal Year Ends | June 30, 2022 |
| Most Recent Quarter (mrq) | December 31, 2022 |
| Next Fiscal Year End | June 30, 2023 |
Profitability
| Profit Margin | 37.23% |
| Operating Margin (ttm) | 57.16% |
| Gross Margin | 89.75% |
| EBITDA Margin | 57.74% |
Management Effectiveness
| Return on Assets (ttm) | 18.35% |
| Return on Equity (ttm) | 21.42% |
Income Statement
| Revenue (ttm) | 70.89M AUD |
| Revenue Per Share (ttm) | 1.44 AUD |
| Quarterly Revenue Growth (yoy) | 19.19% |
| Gross Profit (ttm) | 56.92M AUD |
| EBITDA | 40.94M AUD |
| Net Income Avi to Common (ttm) | 26.4M AUD |
| Diluted EPS (ttm) | 0.4 |
| Quarterly Earnings Growth (yoy) | 94.00% |
Balance Sheet
| Total Cash (mrq) | 140.7M AUD |
| Total Cash Per Share (mrq) | 2.85 AUD |
| Total Debt (mrq) | 1.14M AUD |
| Total Debt/Equity (mrq) | 0.82 AUD |
| Current Ratio (mrq) | 8.798 |
| Book Value Per Share (mrq) | 2.817 |
Cash Flow Statement
| Operating Cash Flow (ttm) | 43.57M AUD |
| Levered Free Cash Flow (ttm) | 38.71M AUD |
Profile of Clinuvel Pharmaceuticals Limited
| Country | Australia |
| State | VIC |
| City | Melbourne |
| Address | 535 Bourke Street |
| ZIP | 3000 |
| Phone | 61 3 9660 4900 |
| Website | https://www.clinuvel.com |
| Industry | Biotechnology |
| Sector(s) | Healthcare |
| Full Time Employees | N/A |
Clinuvel Pharmaceuticals Limited, a biopharmaceutical company, focuses on developing and commercializing treatments for patients with genetic, metabolic, and life-threatening disorders in Australia, Europe, the United States, Switzerland, and internationally. Its lead drug candidate is SCENESSE, a systemic photoprotective drug for the prevention of phototoxicity in adult patients with erythropoietic protoporphyria (EPP). The company's pipeline products include CUV9900, an alpha-melanocyte stimulating hormone analogue; Parvysmelanotide (VLRX001), which provoke prolonged cellular activity; and PRÉNUMBRA, a liquid injectable formulation of afamelanotide. Clinuvel Pharmaceuticals Limited has a collaboration agreement with HK Winhealth Pharma Group Co. Limited t to treat EPP patients with SCENESSE under a named patient program in the People's Republic of China. The company was founded in 1987 and is headquartered in Melbourne, Australia.
Q&A For Clinuvel Pharmaceuticals Limited Stock
What is a current CUV.AX stock price?
Clinuvel Pharmaceuticals Limited CUV.AX stock price today per share is 15.04 AUD.
How to purchase Clinuvel Pharmaceuticals Limited stock?
You can buy CUV.AX shares on the ASX exchange. Contact your financial advisor to select a broker.
What is the ticker symbol for Clinuvel Pharmaceuticals Limited?
The stock symbol or ticker of Clinuvel Pharmaceuticals Limited is CUV.AX.
Which industry does the Clinuvel Pharmaceuticals Limited company belong to?
The Clinuvel Pharmaceuticals Limited industry is Biotechnology.
How many shares does Clinuvel Pharmaceuticals Limited have in circulation?
The max supply of Clinuvel Pharmaceuticals Limited shares is 50.13M.
What is Clinuvel Pharmaceuticals Limited Price to Earnings Ratio (PE Ratio)?
Clinuvel Pharmaceuticals Limited PE Ratio is 26.38596500 now.
What was Clinuvel Pharmaceuticals Limited earnings per share over the trailing 12 months (TTM)?
Clinuvel Pharmaceuticals Limited EPS is 0.57 AUD over the trailing 12 months.
Which sector does the Clinuvel Pharmaceuticals Limited company belong to?
The Clinuvel Pharmaceuticals Limited sector is Healthcare.
Clinuvel Pharmaceuticals Limited CUV.AX included in indexes
| Name Name | Price Price |
24h% 7d chart 24h% & 7d |
VOL Volume | 24h low | 24h high | Volume |
|---|
| Name Name | Price Price |
24h% 7d chart 24h% & 7d |
VOL Volume | 24h low | 24h high | Volume | |
|---|---|---|---|---|---|---|---|
| {{ item.name }} {{ item.symbol }} | {{ item.price }} {{ item.price_usd }} |
{{ item.change_pct }}
|
{{ item.volume }} {{ item.volume_usd }} | {{ item.low }} {{ item.low_usd }} | {{ item.high }} {{ item.high_usd }} | {{ item.components_count }} - | {{ item.volume }} {{ item.volume_usd }} |
| ALL ORDINARIES AORD | 8014.4 AUD 5304.39 USD |
-0.44
|
— — | 7991.2 AUD 5289.03 USD | 8050.6 AUD 5328.35 USD | — - | — — |
| NASDAQ Developed ex US SC NTR G NQDMXUSSCGBPN | 1704.47 GBP 2179.91 USD |
0
|
— — | 1704.47 GBP 2179.91 USD | 1704.47 GBP 2179.91 USD | — - | — — |
| S&P/ASX 200 Net Total Rtn AXNT | 93030.3 AUD 61572.77 USD |
-0.38
|
— — | 92750.3 AUD 61387.45 USD | 93395.1 AUD 61814.22 USD | — - | — — |
| S&P/ASX 200 AXJO | 7758.6 AUD 5135.09 USD |
-0.38
|
— — | 7735.2 AUD 5119.6 USD | 7788.9 AUD 5155.14 USD | — - | — — |
| S&P/ASX ALL AUSTRALIAN 200 AXAT | 7776.9 AUD 5147.2 USD |
-0.37
|
— — | 7753.3 AUD 5131.58 USD | 7806.8 AUD 5166.99 USD | — - | — — |
| S&P/ASX SMALL ORDINARIES AXSO | 3055.7 AUD 2022.44 USD |
-0.94
|
— — | 3042.1 AUD 2013.44 USD | 3084.6 AUD 2041.56 USD | — - | — — |
| S&P/ASX 300 AXKO | 7711.3 AUD 5103.78 USD |
-0.4
|
— — | 7688.2 AUD 5088.49 USD | 7743.1 AUD 5124.83 USD | — - | — — |
| S&P/ASX 200 EQUAL WEIGHT AXEW | 1883.5 AUD 1246.61 USD |
-0.78
|
— — | 1876.4 AUD 1241.91 USD | 1898.4 AUD 1256.47 USD | — - | — — |
- {{ link.label }} {{link}}